ALOFISEL

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug ALOFISEL contains one active pharmaceutical ingredient (API):

1	Darvadstrocel UNII 31W7R94KYT - DARVADSTROCEL
	Darvadstrocel contains expanded adipose stem cells (eASC), which exhibit immunomodulatory and anti-inflammatory effects at inflammation sites.
	Read more about Darvadstrocel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ALOFISEL Suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04	Immunosuppressants	L Antineoplastic and immunomodulating agents
Discover more medicines within L04
L04AX08		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AX Other immunosuppressants
Discover more medicines within L04AX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1768226
ES	Centro de información online de medicamentos de la AEMPS	1171261001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	480329
FR	Base de données publique des médicaments	60511177
GB	Medicines & Healthcare Products Regulatory Agency	368875
IL	מִשְׂרַד הַבְּרִיאוּת	8482
LT	Valstybinė vaistų kontrolės tarnyba	1085323
PL	Rejestru Produktów Leczniczych	100403918
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64494001